Bill Abajian of EastGate Biotech Corp. to Speak at the 2019 M&A Forum for Pharma, Biotech, and Med Device to be Held Between August 12–14, 2019 in Philadelphia

World News: . []

WEST CALDWELL, NJ and TORONTO, ON, June 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that Bill Abajian will be a Speaker at the upcoming 2019 M&A Forum for Pharma, Biotech and Med Device in Philadelphia, PA. The M&A Forum will take place between August 12–14, 2019. The venue for the M&A Forum is the Sheraton Philadelphia University City Hotel in Philadelphia, PA.

Bill Abajian is one of ten confirmed speakers; all of whom will serve as panel participants engaging in individual presentations and case study discussions.  Bill Abajian will be joined by executives from EMD Serono, Novartis International AG, Eli Global, and Acceleron Pharma, to name a few.

Bill Abajian will focus his discussions on how smaller drug companies bring new innovations from Trial to Market.

“We are pleased that Bill Abajian will participate in this high level forum," says Rose C. Perri, President of EastGate Biotech Corp. “The focus of innovative partnership at this forum highlights an instrumental strategy to EastGate’s commercialization plans for its liquid insulin mouth rinse for Type 2 diabetes patients in the future and we are very pleased that the company has this opportunity to share its own experience with other global pharmas,” concludes Rose Perri.

EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increase the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. EastGate's wholly owned subsidiary Omni Surgery and Anti-Aging Centre is the first of many surgery centers to come under the Omni umbrella as we plan to roll up existing business under the Omni brand and expand our footprint globally.

CONTACT:
Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com

More news and information about Eastgate Biotech Corp.

Published By:

Globe Newswire: 14:15 GMT Wednesday 12th June 2019

Published: .

Search for other references to "bill" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us